Stock Scorecard



Stock Summary for Legend Biotech Corp (LEGN) - $34.37 as of 8/29/2025 3:35:17 PM EST

Total Score

8 out of 30

Safety Score

40 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for LEGN

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for LEGN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for LEGN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for LEGN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for LEGN (40 out of 100)

Stock Price Rating (Max of 10) 8
Historical Stock Price Rating (Max of 10) 8
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 5
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 8
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for LEGN

OncoC4 Strengthens Leadership Team with Appointment of Shiniu Wei as Chief Financial Officer 8/18/2025 12:00:00 PM
Legend Biotech Appoints Carlos Santos as Chief Financial Officer 8/18/2025 12:00:00 PM
Company News for Aug 12, 2025 8/12/2025 11:22:00 AM
Key Inflation Data in Focus 8/11/2025 2:53:00 PM
Pre-Markets in Green, Inflation Data, Retail Sales, Q2 Earnings This Week 8/11/2025 2:12:00 PM
Legend Biotech to Host Investor Conference Call on Second Quarter 2025 Results 7/28/2025 12:00:00 PM
Legend Biotech ( LEGN ) Surges 6.0%: Is This an Indication of Further Gains? 7/18/2025 11:24:00 AM
Is Legend Biotech Gaining or Losing Market Support? - Legend Biotech ( NASDAQ:LEGN ) 6/12/2025 2:01:00 PM
Quanex Building Products, Manchester United, Byrna Technologies And Other Big Stocks Moving Higher On Friday - AeroVironment ( NASDAQ:AVAV ) , Applied Digital ( NASDAQ:APLD ) 6/6/2025 2:20:00 PM
Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting 6/3/2025 2:45:00 PM

Financial Details for LEGN

Company Overview

Ticker LEGN
Company Name Legend Biotech Corp
Country USA
Description Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology and other indications in North America and internationally.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 6/30/2025
Next Earnings Date 11/24/2025

Stock Price History

Last Day Price 34.37
Price 4 Years Ago 46.61
Last Day Price Updated 8/29/2025 3:35:17 PM EST
Last Day Volume 881,225
Average Daily Volume 1,082,951
52-Week High 59.62
52-Week Low 27.34
Last Price to 52 Week Low 25.71%

Valuation Measures

Trailing PE N/A
Industry PE 40.47
Sector PE 60.89
5-Year Average PE -39.30
Free Cash Flow Ratio 23.87
Industry Free Cash Flow Ratio 15.46
Sector Free Cash Flow Ratio 30.76
Current Ratio Most Recent Quarter 4.71
Total Cash Per Share 1.44
Book Value Per Share Most Recent Quarter 5.61
Price to Book Ratio 6.19
Industry Price to Book Ratio 28.68
Sector Price to Book Ratio 26.74
Price to Sales Ratio Twelve Trailing Months 7.96
Industry Price to Sales Ratio Twelve Trailing Months 25.19
Sector Price to Sales Ratio Twelve Trailing Months 13.32
Analyst Buy Ratings 11
Analyst Strong Buy Ratings 8

Share Statistics

Total Shares Outstanding 184,571,000
Market Capitalization 6,343,705,270
Institutional Ownership 47.33%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 65.84%
Reported EPS 12 Trailing Months -1.78
Reported EPS Past Year -0.51
Reported EPS Prior Year -0.80
Net Income Twelve Trailing Months -325,773,776
Net Income Past Year -177,026,000
Net Income Prior Year -518,254,000
Quarterly Revenue Growth YOY 36.70%
5-Year Revenue Growth 61.40%
Operating Margin Twelve Trailing Months -8.58%

Balance Sheet

Total Cash Most Recent Quarter 266,660,581
Total Cash Past Year 286,749,000
Total Cash Prior Year 1,277,713,000
Net Cash Position Most Recent Quarter -43,603,419
Net Cash Position Past Year -14,447,000
Long Term Debt Past Year 301,196,000
Long Term Debt Prior Year 281,328,000
Total Debt Most Recent Quarter 310,264,000
Equity to Debt Ratio Past Year 0.78
Equity to Debt Ratio Most Recent Quarter 0.77
Total Stockholder Equity Past Year 1,040,546,000
Total Stockholder Equity Prior Year 1,251,371,000
Total Stockholder Equity Most Recent Quarter 1,035,556,790

Free Cash Flow

Free Cash Flow Twelve Trailing Months -290,365,000
Free Cash Flow Per Share Twelve Trailing Months -1.57
Free Cash Flow Past Year -158,138,000
Free Cash Flow Prior Year -415,998,000

Options

Put/Call Ratio 0.06
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -1.03
MACD Signal -0.70
20-Day Bollinger Lower Band 27.25
20-Day Bollinger Middle Band 35.05
20-Day Bollinger Upper Band 42.85
Beta 0.26
RSI 34.86
50-Day SMA 37.81
150-Day SMA 50.85
200-Day SMA 49.17

System

Modified 8/30/2025 3:37:30 AM EST